Cheryl Czerlanis, MD, shares insights from her ASCO 2025 presentation on the topic.
Lung Cancer
Advertisement
The study participants include those who have had at least one first-degree relative diagnosed with lung cancer.
The organization also granted priority review, breakthrough designation, and orphan drug designation to the application.
The study compared results from North America with global results by high-income and low- or middle-income countries.
Cheryl Czerlanis, MD, shares insights from the session on lung cancer screening that she chaired at ASCO 2025.
Palliative care researchers discuss differences in lung cancer treatment disparities across Hispanic patient subgroups.
Helena Yu, MD, discusses research updates from REZILIENT1 that were presented at ASCO 2025.
Coral Olazagasti, MD, and Maria Velez, MD, MS, reflect on the opportunities at the ASCO Annual Meeting.
Coral Olazagasti, MD, shares why the ASCO Annual Meeting is a critical time to bring the field together.
Dr. Singhi unpacks the thoracic oncology data and highlights coming up at this year's ASCO Annual Meeting.
Mara Antonoff, MD, explains the nuances of determining if a patient with oligometastatic disease is a candidate for surgery.
A study of nearly 10,000 lung cancer cases found that only 41% would have been eligible for screening per USPSTF guidelines.
The study is evaluating if hydrogen peroxide in exhaled breath condensate can be used as a biomarker for lung cancer.
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.